Dr Sif Ormarsdottir | Specialist Gastroenterology and Hepatology, Chair, Hepatotoxicity Safety Knowledge Group,
AstraZeneca Ab

Dr Ormarsdottir graduated with a MD from the University of Iceland. She did her training at the University hospital in Uppsala, Sweden in Internal Medicine and Gastroenterology and Hepatology, where she then held position as a consultant. She did her PhD in medicine on research related to bone metabolism in chronic liver disease. In 2001 Sif was employed by the Medical Products Agency in Sweden as a clinical assessor/senior expert. In 2003, she moved to the Icelandic Medicines Agency and at the same time started her own private practice, which she maintained until 2010. Her regulatory work has mainly been concerned with EU centralized procedures, co-ordinated by the European Medicines Agency, EMA. Between 2004-2010 she was a member of the CHMP and the SAWP. She was the co-rapporteur for several centralized drug applications and a coordinator for a large number of scientific advices. As a member of the EWP, she was the coordinator for three regulatory guidelines in the field of gastroenterology and in 2010 she became the chair of the Gastroenterology Drafting Group at the EMA. In 2011 Sif joined AstraZeneca as Associate Director Physician/Liver Safety Expert. She currently chairs and is the clinical lead of the Hepatotoxicity Safety Knowledge Group at AstraZeneca. Since 2014, she is a Steering Committee member of the EU IMI SAFE-T consortium.